Roivant Sciences Ltd (ROIV) - News Archive

In a significant development for the management of uncontrolled Graves disease (GD), Immunovant, Inc. has released pivotal data concerning its investigational therapy, batoclimab. The findings, which will be formally pr...

The field of immunology continues to evolve with promising advancements in therapeutic options for autoimmune diseases. A noteworthy development is the emergence of batoclimab, an investigational fully human IgG1 monocl...

In a significant move within the biopharmaceutical landscape, Roivant Sciences Ltd. announced on February 25, 2025, a notable reshuffle in the Board of Directors of Arbutus Biopharma Corporation. All former Board member...

Breaking News: Roivant Sciences Innovative VTAMA Cream Gains Approval for Plaque Psoriasis Treatment; FDA Review for Atopic Dermatitis UnderwaySeptember 10, 2024 - In a significant advancement for psoriasis management,...

In a landscape where medical advancements are critical for combating respiratory and autoimmune diseases, Pulmovant and its sister company, Immunovant, recently showcased promising innovations. Yesterday, at the Europea...

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to improving the lives of individuals with autoimmune diseases, has recently released promising updates on their development programs target...

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Mil...

Immunovant, a clinical-stage immunology company, has reported highly encouraging results from the initial cohort of patients in a 24-week Phase 2 clinical trial for batoclimab, a potential breakthrough therapy for Grave...

BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 - In a groundbreaking move, Roivant (Nasdaq: ROIV) announced today the successful completion of the long-awaited acquisition of Telavant by Roche (SIX: RO, ROG;...

Roivant s IMVT-1402 Demonstrates Best-in-Class Potential in Phase 1 Clinical Trial, Potentially Revolutionizing Treatment for Autoimmune DiseasesImmunovant, Inc. (Nasdaq: IMVT), a leading clinical-stage immunology compa...

In a recent development, Roivant and Priovant announced that their Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus failed to meet its primary endpoint. Despite this setb...